title: Ventromedial hypothalamic melanocortin receptor activation: regulation of activity energy expenditure and skeletal muscle thermogenesis.
abstract: The ventromedial hypothalamus (VMH) and the central melanocortin system both play vital roles in regulating energy balance by modulating energy intake and utilization. Recent evidence suggests that activation of the VMH alters skeletal muscle metabolism. We show that intra-VMH melanocortin receptor activation increases energy expenditure and physical activity, switches fuel utilization to fats, and lowers work efficiency such that excess calories are dissipated by skeletal muscle as heat. We also show that intra-VMH melanocortin receptor activation increases sympathetic nervous system outflow to skeletal muscle. Intra-VMH melanocortin receptor activation also induced significant changes in the expression of mediators of energy expenditure in muscle. These results support the role of melanocortin receptors in the VMH in the modulation of skeletal muscle metabolism.
  
  
  
  The ventromedial hypothalamus (VMH) and the brain melanocortin system both play vital roles in increasing energy expenditure (EE) and physical activity, decreasing appetite and modulating sympathetic nervous system (SNS) outflow. Because of recent evidence showing that VMH activation modulates skeletal muscle metabolism, we propose the existence of an axis between the VMH and skeletal muscle, modulated by brain melanocortins, modelled on the brain control of brown adipose tissue. Activation of melanocortin receptors in the VMH of rats using a non-specific agonist melanotan II (MTII), compared to vehicle, increased oxygen consumption and EE and decreased the respiratory exchange ratio. Intra-VMH MTII enhanced activity-related EE even when activity levels were held constant. MTII treatment increased gastrocnemius muscle heat dissipation during controlled activity, as well as in the home cage. Compared to vehicle-treated rats, rats with intra-VMH melanocortin receptor activation had higher skeletal muscle norepinephrine turnover, indicating an increased SNS drive to muscle. Lastly, intra-VMH MTII induced mRNA expression of muscle energetic mediators, whereas short-term changes at the protein level were primarily limited to phosphorylation events. These results support the hypothesis that melanocortin peptides act in the VMH to increase EE by lowering the economy of activity via the enhanced expression of mediators of EE in the periphery including skeletal muscle. The data are consistent with the role of melanocortins in the VMH in the modulation of skeletal muscle metabolism.
authors.affiliation: School of Biomedical Sciences, Kent State University, Kent, OH, USA. cgavini@luc.edu.|Department of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. cgavini@luc.edu.
authors.forename: Chaitanya K
authors.identifier: 0000-0003-4083-554X
authors.initials: CK
authors.lastname: Gavini
authors.affiliation: Department of Exercise Science/Physiology, College of Education, Health, and Human Services, Kent State University, Kent, OH, USA.
authors.forename: William C
authors.initials: WC
authors.lastname: Jones
authors.affiliation: School of Biomedical Sciences, Kent State University, Kent, OH, USA.|Department of Biological Sciences, Kent State University, Kent, OH, USA.
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Novak
mesh_terms: D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D052436:Adipose Tissue, White / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D000818:Animals; D004734:Energy Metabolism; D007031:Hypothalamus / Q000502:physiology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D009638:Norepinephrine / Q000378:metabolism; D010456:Peptides, Cyclic / Q000494:pharmacology; D010805:Physical Conditioning, Animal; D017207:Rats, Sprague-Dawley; D044101:Receptors, Melanocortin / Q000819:agonists / Q000502:physiology*; D022722:Thermogenesis; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D010456:Peptides, Cyclic; D044101:Receptors, Melanocortin; C079282:melanotan-II; D000521:alpha-MSH; D009638:Norepinephrine